Conference Call Access
Domestic Dial In: (888) 674-0224
International Dial-In: (201) 604-0502
Interested parties may also listen to the web cast by clicking on the following link to register and then joining the live event with the same URL:
http://www.kingpharm.com/Investors/Webcasts.cfm
If you are unable to participate during the live event, the replay number is 888-632-8973, or 201-499-0429 if you are calling from outside the USA. The replay code is 88910347 followed by the # sign. The web cast of our call on November 5th will be archived on King's web site, accessible through the link above, for not less than 14 days.
King, headquartered in Bristol, Tennessee, is a vertically integrated branded pharmaceutical company. King, an S&P 500 Index company, seeks to capitalize on opportunities in the pharmaceutical industry through the development, including through in-licensing arrangements and acquisitions, of novel branded prescription pharmaceutical products and technologies that complement the Company's focus in specialty-driven markets, particularly neuroscience and hospital. King's wholly owned subsidiary, Alpharma Inc., is also a leader in the development, registration, manufacture and marketing of pharmaceutical products for food producing animals.
This release contains forward-looking statements which reflect management's current views of future events and operations, including, but not limited to, statements pertaining to the anticipated date for release of the Company's financial results for the second quarter ended June 30, 2009. These forward-looking statements involve certain significant risks and uncertainties, and actual results may differ materially from the forward-looking statements. Some important factors which may cause results to differ include King's ability to release the Company's financial results as currently planned on November 5, 2009. Other important factors that may cause actual results to differ materially from the forward-looking statements are discussed in the "Risk Factors" section and other sections of King's Form 10-K for the year ended December 31, 2008 and Form 10-Q for the quarter ended March 31, 2009 which are on file with the U.S. Securities and Exchange Commission. King does not undertake to publicly update or revise any of its forward-looking statements even if experience or future changes show that the indicated results or events will not be realized.
SOURCE: King Pharmaceuticals, Inc.
King Pharmaceuticals, Inc. Jack Howarth, Vice President, Investor Relations 908-429-8350

More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index